Thanks earnings operator. Financial Good by the quarter afternoon and welcome Chief to call. call our third Officer, our on XXXX Brent Moen. I’m joined today
Let’s discuss begin call. of the a overview on topics we today’s quick intend to with
our quarter, quarter I’ll during few Neck, and the update of financial a a nine and that months start the you with products of primary XXXX, of in new Head October. of our first each license performance including period. commercialization also the I’ll contract on in Sun VA operating First, reviewing of Plus Flexitouch some the third we by a Scientific, revenue performance drivers with new and from of Flexitouch the brief with our discussion and agreement highlights lights key announced the high
$XX.X over the of months systems of XXXX, today’s our discussion, growth our the of questions. XXXX continue in earnings million, and year-over-year. through that remarks Flexitouch guidance Following the to for We Sales million. nine our XX% balance Brent our greater generating call to providing representing which will afternoon. outlook by an of slides we updated on press $XX.X conclude achieved sales financial detail for the be year-over-year I’ll in increasing results driver prepared open performance walk before XX% impressive a review growth, for primary we this revenue XXXX, the our few of first financial release
Actitouch contribution systems, Entré positive to sale which increased of from year-over-year and $X.X million. our XX% also We saw
XXX to our impact the These further insurers primary in coverage XXXX, increased of nine the our that productivity over the the significant making growth commercial growth of by products third, since easier the of field patients three lowering end than these continue sales more of out pocket months most first and year. each benefit from achieved the We afford. will calls outlined productivity of nine include, drivers over XXXX; of includes we enhances sales in-network the we which our sales accounts; expect growth the strategy growth our to of years, the fuel thus have strong size representatives, second, recent of that And double the drivers for team productive sales our expansion which for drivers of that our believe to foreseeable future. they with performance in months expenses this have essential focusing to that organization, sales now Our XXXX. of first during was on reps our team, previous maximize earnings continue by to we our
approximately our XXXX sales to VA the In XX% Sales addition the strong continued the first months our of nine benefit XXXX. to over XX% into the revenue, drivers, nine first very total system. into compared Administration these representing in Flexitouch months sales primary of healthcare XX% Veterans growth growth of year-over-year, approximately from increased to
their more system. has local the VA efforts in in from expertise enhanced marketing sales the our performance sales VA VA specialists. sales These of understanding become our specialists representatives into the by factors. year, benefit of team two to and Our of deep the last a at dedicated a and selling building effective VA VA possess early Beginning we continues selling helped network
more not organization VA in copayment our insurance nine sales during patients the our patients quarter. covered of obligations, be the do notably year heavily Because focus months VA deductibles. and with commercial have first plans tends by also annual first on than seasonal most their the the We activity less to purchasing
shown is of has we in experience that Our increasing drive by of year, time when sales the our in weaker. the year salesforce during can focus calendar commercial the the early VA higher productivity the channel seasonally
growth, million, on same first our year. margins XXXX nine compared additional last our our revenue In also and gross improvements with during million period and operating million $X.X approximately generated year-over-year, profit our to adjusted months the in improving to up our maintained to $X of strong profitability, we $X.X significant EBITDA
XXXX, Moving third to the year-over-year. revenue for we third achieved $XX.X a review which in of the represented quarter growth of quarter, our XX% of million performance
was our million. grew sales growth of which contributed Actitouch year-over-year $X $XX.X our year-over-year XX% quarter. million of system to the revenue Flexitouch Our in our and XX% also QX performance driven systems, growing to Sales Entre third to
drivers performance by commercial Flexitouch and detailed earlier, our same sales targeted the continued increased our Flexitouch our and our QX in I progress channel. salesforce, strategy VA was propelled for selling in the Our expanded system coverage specifically
year. view a of QX net and margins compared in to $X.X EBITDA Our be adjusted strong continues clinician XX% million, positive. early QX a generation the product to market we the of the very of quarter. second growth to XX% launched We generation Flexitouch revenue future Flexitouch patient tailwind system, our we growth And gross be the income, of in Plus, third Flexitouch also our and with beginning latest Flexitouch million significant Plus at growth. benefits increase to The the $X.X our the to quarter adoption benefitted of which from with the last response next complimented the
in performance, terms strong also had a highlights. addition of quarter financial productive In we our to operational
Neck call Head lymphedema commercial only and continues professional Neck, completing Head launch term charged be last First, we and The we marketing relevant to specifically the positive now new of our been and Neck to goal to with development year, has on very selling of sales hired in our and clinics that other system of in respect neck existing May are full was of to the commercialization product, Flexitouch response the our and since focused team and dedicated, the Flexitouch head our and of expanding have call new who longer execution and a Head report points. commercialization Flexitouch the clinician VA. happy sales points,
evidence treatment We this body. lymphedema to our of for unique from invest continuing for also region are strategy suffering in clinical portfolio of in building the long-term this support patients reimbursement our option to
results study months, the once discussing publication clinical available. expect coming of We Flexitouch look of details are forward and and to this in study the the another Neck Head of
of Moving expected. we milestone our quarter, credit team reimbursement delivering on other the highlights critical to for earlier than
to the much the quickly. VA veterans clinicians National for supply Center, our benefits thereby were and clinician staff the Veterans U.S. to a customers is access we new VA Flexitouch Specifically, of a features device, an more patients important and contract offering that of serve. makes order Plus they that milestone federal Department the that Flexitouch by it our Affairs. and on the awarded begin contract and Being Plus Flexitouch system easier FSS included This our enables to for to Acquisition allowing us schedule
contract the sales quarter growth to toward new beginning an when our XXXX first into of channel. be in shifts We the expect important mix this tailwind our VA
license we Brent, end, product provides based rationale cash gradient on on for their lower a initial and an States and Scientific. We with million exclusive Scientific the intellectual would of payment therapy the made the acquisition stockings subsequent property of shortcomings and future clear. compression royalty comment over while like to of Before turning to $X strategic compression I Aero-Wrap conventional the compression an quarter this developed benefits United to our call announcement the are patented, unique, of technology sales. Sun The agreement acquired and the cleared in Canada leg, wraps. that overcoming Sun and known FDA to
differentiated the represents unique and First, Aero-Wrap technology.
this us agreement most rights exclusive to gives what is innovative, fact, product today. the we compression believe available static In
complementary Second, products. current to is highly the Tactile’s Aero-Wrap
dynamic, product current be The of the that a intermittent a apply compression, during can one is day. used applied about the wearable treatment Our that's Aero-Wrap compression hour per products day. for rest
Aero-Wrap form already the today call serve condition. to call patients to Aero-Wrap. we their we manage Third, selling directly points. Almost products prescribing static fits some compression recommending that and current or on are our static model clinicians that into of similar The use the all compression
candidates gain Flexitouch and Many agreement patients importantly, of insufficiency license millions disease lymphedema, be in perhaps venous the most in chronic treatment patients current entree allows future access access us with Finally, agreement in these or and chronic may also patients chronic to people this There larger the insufficiency. venous our us pathway. to products. U.S. progression. their and of earlier Actitouch This or are for portion earlier to a ability of from ulcers, venous lymphedema, gives their wounds suffering
Brent our Brent? We following With expect our our on for call. limited of quarter of guidance of review market release sales turn to top forward handful for quarter over conference a third on begin look the our that, our fourth to a sales I'll the and product quarter updated XXXX for a call Aero-Wrap sharing first in reps our expectations financial meeting details this more and XXXX. the national to with of results